igm-2323
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04082936)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594476 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06524687 | Phase 1 | Jul 31, 2024 | IGM Biosciences, Inc. |
| NCT06087406 | Phase 1 | Sep 13, 2023 | IGM Biosciences, Inc. |
| NCT06041568 | Phase 1 | Aug 15, 2023 | IGM Biosciences, Inc. |
| NCT04082936 | Phase 1 | Sep 30, 2019 | IGM Biosciences, Inc. |
| NCT06331832 | N/A | — | IGM Biosciences, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IGM Biosciences, Inc. | For profit | 5 | 5 | 2 | 2019 |
1 organizations
Page 1 / 1